GSK has sold part of its shareholding in its former consumer healthcare business, Haleon, raising around £885.6m.
Haleon became an independent company listed on the London Stock Exchange in July 2022, with GSK initially retaining a 12.94% stake. In May, GSK sold 240 million ordinary shares in the business, reducing its stake to approximately 10.3%.
The FTSE 100 biopharma company has now sold a further 270 million ordinary shares in Haleon, taking its holding to 685 million ordinary shares or approximately 7.4%.
The shares were sold in a placing to institutional investors.
GSK and Pfizer, which holds a 32% stake in Haleon, have each undertaken not to dispose of any further shares in Haleon for a period of 60 days following the latest sale.
Haleon’s brands include Sensodyne, Centrum, Panadol and Advil.
